Evolution Biotechnologies – Austin, Texas, May 20th 2021

Austin, Texas, May 20th 2021

Evolution Biotechnologies Inc., the Texas-based company extending the use of biological control into medically important areas, today announces the publication of an interview by Phage Directory (https://phage.directory/) in its online news source “Capsid and Tail”, under the title “Phages Before the Phrenzy: Part I — An interview with Dr. David Harper, CEO of Evolution Biotechnologies”.

The interview by Curtis Hoffmann is based on a discussions at the Phage Futures meeting in 2019, updated to reflect developments since that time.

The interview is available at: https://phage.directory/capsid/phages-before-the-phrenzy#article

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant infections in companion animals.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us